Navigation Links
Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
Date:10/23/2007

http://www.genaera.com" target="_new">http://www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding these preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Gen
'/>"/>

SOURCE Genaera Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
2. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
3. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
5. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
6. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
7. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... 2014  BioSpecifics Technologies Corp. (NASDAQ: BSTC ), ... as XIAFLEX ® in the U.S. and XIAPEX ® ... Tom Wegman , will present a corporate overview at the ... Conference. The presentation will take place on ... Millennium Broadway Hotel in New York, NY ...
(Date:9/19/2014)... LONDON , September 19, 2014 ... hat Pharma IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, ... abdeckt. Die interaktive PDF, verfügbar unter pharmaserialisation.com ... an dem sie jeweils in Kraft treten. ... der Serialisierung nicht länger um das "ob", sondern ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
... May 20 BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: ... treatment in the Phase 1 clinical study of ... of,phenylketonuria (PKU). The study is expected to conclude ... are dedicated to serving the PKU community and ...
... Claims Suggests a Benefit,of Anti-Tumor Necrosis Factor Therapies on Absenteeism Among ... ... Data from a new analysis of the,Active Ulcerative Colitis Trials (ACT ... percent of patients with moderately to severely active,ulcerative colitis (UC) receiving ...
Cached Medicine Technology:BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU 2BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU 3New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 2New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 3New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 4New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 5New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 6New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 8
(Date:9/20/2014)... September 20, 2014 The excitement is building up ... Airy, North Carolina. This year the Surry Arts Council will ... from around the country who are still fans of the Andy ... a sitcom that aired on CBS from 1960 through 1968. ... in American television history. Mount Airy, North Carolina is where ...
(Date:9/20/2014)... 20, 2014 Recently, UWDress.com, an innovative ... women’s special occasion outfits, has launched a special offer ... prom outfits are popular among worldwide clients. Now, all ... prom dresses on its website. , Additionally, ... from around the world. Great custom made items can ...
(Date:9/20/2014)... Wisconsin (PRWEB) September 20, 2014 QueenBeeTickets.com ... the young star’s tour performances. She will visit many ... of February until the 16th of April. , ... Grande Honeymoon Tour tickets at QueenBeeTickets.com. , The star’s ... opportunity to see their favorite young singer in a ...
(Date:9/20/2014)... The Arizona Advanced Manufacturing Institute ... Manufacturing Day by opening its doors to the community. ... manufacturing labs will be offered between 10 a.m. and ... and Dobson campus (1833 W. Southern Ave, Mesa, AZ ... The AzAMI at MCC was established in the fall ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 MarijuanaDoctors.com ... successful showing at the PAIN Week conference that ... Hotel and Casino in Las Vegas from September ... primarily attended PAIN Week in the hopes of ... a viable and legitimate tool to treat chronic ...
Breaking Medicine News(10 mins):Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Discounted 2014 Prom Dresses Provided By Innovative Company UWDress.com 2Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2
... 1 As the economic crisis deepens, SilverCensus.com ... a national web site for caregivers, senior citizens, ... urging American Veterans to investigate and take advantage ... called "Aid and Attendance." ...
... Mass., April 1, EnVivo Pharmaceuticals today ... Corporation (MTPC) for the development and commercialization ... Japan and several other Asian countries. EVP-6124 ... agonist currently in development for cognition enhancement ...
... Laboratories, Inc. Immunotech Laboratories announces successful Participation in ... its abstract " Irreversible Pepsin Fraction (IPF) displays ... in vitro investigation of activity on human lymphocytes." ... Conference on Clinical and Social Research on AIDS ...
... worse cholesterol, blood vessel health than with South Beach, Ornish ... the "maintenance" phase that occurs after initial weight loss, the ... on the heart than the high-fat, low-carbohydrate Atkins regimen, a ... diets to see which might be better at achieving weight ...
... April 1 Harvest Technologies Corp. ... study report was completed for the first thirty (30) ... non-reconstructable critical limb ischemia due to advanced thromboangitis obliterans, ... is being conducted at Sri Ramachandra University in Chennai ...
... VC Business Practices to Funding ResearchTUCSON, Ariz., April 1 ... launch of a new initiative, MDA Venture Philanthropy (MVP), ... A 501(c)(3) nonprofit organization, MVP will break with traditional ... of venture capital firms to fast track the development ...
Cached Medicine News:Health News:Little-Known VA Care Entitlement for Veterans Highlighted by SilverCensus.com 2Health News:Little-Known VA Care Entitlement for Veterans Highlighted by SilverCensus.com 3Health News:EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries 2Health News:EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries 3Health News:Beating a Global Killer: HIV/AIDS 2Health News:Beating a Global Killer: HIV/AIDS 3Health News:Beating a Global Killer: HIV/AIDS 4Health News:Atkins Diet Tougher on Heart After Weight Loss 2Health News:Atkins Diet Tougher on Heart After Weight Loss 3Health News:Harvest Technologies Announces Interim Study Results From Critical Limb Ischemia Trial in Chennai India 2Health News:Harvest Technologies Announces Interim Study Results From Critical Limb Ischemia Trial in Chennai India 3Health News:Muscular Dystrophy Association Launches New Venture Philanthropy 2Health News:Muscular Dystrophy Association Launches New Venture Philanthropy 3
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Inquire...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
Medicine Products: